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Background: The study was aimed to evaluate the anti-inflammatory activity of ethanolic and aqueous extracts of
Polygonum minus (Huds) using in vitro and in vivo approaches.
Methods: The in vitro tests used to evaluate ethanolic extract are cyclooxygenase-1 (COX-1), cyclooxygenase-2
(COX-2), lipooxygenase (5-LOX), secretory phospholipase-A2 (sPLA2) inhibition assay whilst the in-vivo effect was
measured by the ability of aqueous extracts to reduce paw edema induced by λ-carrageenan, in rats.
Results: The ethanolic extract inhibited the activities of 5-LOX and COX-1(p < 0.05) whilst the inhibitory effect on
COX-2 was only moderate. A marked inhibition of 5-LOX was observed at 30 μg/ ml. The extract did not inhibit the
activity of sPLA2. The ability of the ethanolic extracts of Polygonum minus to inhibit both 5-LOX and COX, prompted
a study to evaluate the effects of using an aqueous extract of Polygonum minus (LineminusTM); as this would be
more suitable for future clinical testing. The anti-inhibitory activity of the aqueous extract from this plant was
evaluated using a rat model where inflammation was induced in the paws by injection of λ-carrageenan. The
aqueous extracts from Polygonum minus administered at doses of 100 and 300 mg/kg body weight (b.w.), significantly
(p < 0.01) reduced paw edema induced by λ-carrageenan in the experimental model, at 4 h compared to the vehicle
control. Furthermore, administration of 100 mg/kg b.w. or 300 mg/kg b.w. completely reduced inflammation of the
paw 4 h after injection.
Conclusion: These findings suggest that aqueous extract of Polygonum minus possesses potent anti-inflammatory
activities.
Keywords: Inflammation, Polygonum minus (Huds), Paw edema, Cyclooxygenase, Lipooxygenase, Secretory
phospholipase-A2Background
Inflammatory reaction, typically characterized by redness,
swelling, heat, and pain is one of the most important host
defense mechanisms against invading pathogens. How-
ever, persistent or over-inflammation can result in tissue
damage and possibly failure of vital organs. In a number
of pathological conditions, acute and/or chronic inflam-
mation can lead to acute or chronic inflammatory dis-
eases such as septic shock, rheumatoid arthritis, gastritis,* Correspondence: annie.g@biotropicsmalaysia.com
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unless otherwise stated.and atherosclerosis [1,2]. Over a period of time, inflam-
mation due to trauma, genetic predisposition, stress and
age can cause damage to cells of the body, thus releasing
various membrane components that can activate the in-
flammatory process. The phospholipids liberated from
the lipid bilayer membrane can be converted to arachi-
donic acid (AA) by the enzyme phospholipase A2
(PLA2). Arachidonic acid produced plays an important
role in many metabolic pathways and is useful when pro-
duced in moderation. However in cases of severe inflam-
mation such as joint damage, the AA is produced in
excess [3]. Excess AA is converted by the cyclooxygenase
(COX) and lipooxygenase (LOX) pathways into powerfulLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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and leukotrienes (LT), respectively [4,5].
In the past few years, there has been concerted re-
search focusing on the LOX pathway as controlling this
pathway can play an important role in the relief of joint
pain. The LOX pathway is a parallel inflammatory pathway
to the COX pathway, where the AA produced is converted
to LT, one of the strongest chemotactic agent produced in
the body [6,7]. If left unregulated, these inflammatory path-
ways can cause joint damage. Cyclooxygenase-1(COX-1)
and 5-lipooxygenase (5-LOX) are key enzymes involved
in the formation of pro-inflammatory mediators such as
eicosanoids from AA [8]. The COX-1 is constitutively
expressed in many tissues and PGs produced by the action
of COX-1 mediate housekeeping functions such as cyto-
protection of gastric mucosa, regulation of renal blood flow
and platelet aggregation, mostly through formation of ei-
cosanoids from AA [9]. The 5-LOX enzyme plays a key
role in the metabolism of AA to produce leukotrienes. Sev-
eral studies suggest that there is a link between 5-LOX and
carcinogenesis due to inflammation in human and animals
[10]. Leukotrienes also play crucial roles as mediators in
allergy and inflammation [11]. In addition, these pro-
inflammatory mediators are also linked to some of
the pathophysiological conditions of the brain such as
cerebral ischemia, brain edema and brain tumors due to
increased permeability of the blood–brain barrier (BBB)
[12]. The 5-LOX enzyme is expressed in human brain tu-
mors [10], hence it may play a role in inducing brain
edema which causes brain tumor.
In the recent years, the use of herbal remedies for the
treatment of inflammatory disease has been gaining mo-
mentum [13]. There has been some concern over the
use of COX-2 inhibitors ie rofecoxib and valdecoxib for
therapeutic interventions, causing some of these thera-
peutic products to be either withdrawn or made to carry
a warning by the Food and Drug Authority (FDA) of the
USA [14,15]. Due to risk of cardiovascular and skin re-
lated toxicities, rofecoxib and valdecoxib were with-
drawn from the market in September 2004 and March
2005 respectively [16]. On the other hand, inhibitors of
the 5-LOX enzyme that are of herbal origin are reported
to offer significant relief and do not appear to have any
adverse effects. Therefore, 5-LOX inhibitors of plant
origin are gradually becoming the preferred choice of
treatment for some of the diseases due to chronic in-
flammation [17,18].
Polygonum minus [(Huds) (Polygonaceae)] is a small
herbaceous plant commonly known in Malaysia as
Kesum [19]. This plant is a small, annual, slender, glab-
rous and erect to ascending herb, with tall or long
branches [19]. This plant has a sweet and pleasant aroma
and is commonly used by Malaysians as a flavoring ingre-
dient [20] in Malaysian local dishes such as Laksa, NasiKerabu and Nasi Ulam [21]. Traditionally, this plant has
been used to treat digestive disorders and dandruff. It is
also used in the perfume industry because of its volatile oil
[22,23]. It has proven to be a potent natural source of anti-
oxidants and there are several reports that claim that it has
a high level of free radical scavenging activity and reducing
power [24]. Flavonoids have been reported in Polygonum
minus [25] and these phenolic compounds have been asso-
ciated with anti-inflammatory effects [26], but none reports
anti-inflammatory effects of Polygonum minus.
Meanwhile, safety studies such as acute and sub-
acute toxicity of aqueous extract of Polygonum minus
(biotropics®PM101), in Wistar rats has shown that
the no-observed-adverse-effect-level (NOAEL) follow-
ing oral administration for 28 days, to be more than
1000 mg/kg body weight [27]. The aqueous, ether and
ethanol extracts of Polygonum minus have also been ex-
tensively studied for their phenolic content, anti-oxidant
and cytoprotective activity [28], hence this study is to
investigate whether Polygonum minus extracts possess
anti-inflammatory activity as a result of flavonoids con-
tent and antioxidant property.
In the present study, we investigated the anti-
inflammatory activities of extracts obtained from the
aerial parts consisting stem and leaves of Polygonum
minus using in vitro and in vivo approaches.
Methods
Chemicals and drugs
The chemicals λ-carrageenan, diclofenac sodium and car-
boxy methyl cellulose (CMC) were purchased from Sigma-
Aldrich Chemical Co. in Mumbai, India. Cyclooxygenase
(COX) Inhibitory Screening Assay Kit, Lipoxygenase
(5-LOX) Inhibitor Screening Assay Kit, Secretory Phospho-
lipase A2 (sPLA2) (Type V) Inhibitor Screening Assay Kit,
Diclofenac, Nordihydroguaiaretic acid (NGDA) and Arachi-
donic Thioester Phosphatidylcholine (TEPC) were procured
from Cayman Chemical Company (Tallinn, Estonia).
Plant material
Polygonum minus was procured from Biotropics Malaysia
Berhad, Malaysia. The plant material was identified on the
basis of exomorphic characters and review of literature
by a Taxonomist from Institute Bio Science, University
Putra Malaysia (UPM). The voucher specimen of the plant
(SK 2077/12) was deposited in the Herbarium, Institute
Bioscience UPM of Malaysia. The aerial parts comprising
the stem and leaves were extracted using different extrac-
tion techniques to produce ethanol extract for in-vitro as-
says and aqueous extract for in-vivo assay.
Extract preparation for in-vitro assays
The aerial parts were dried by oven drying at a
temperature of 40°C for 48 hours and shredded to 2 to
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were subjected to an organic extraction with 750 ml
90%:10% (v/v) ethanol: water mixture with aid of sonic-
ation at maximum temperature of 40°C for 30 minutes.
The solvents were reduced by evaporation on a rotary
evaporator at reduced pressure (15 mbar) to approxi-
mately 50 ml. The remaining mixture was added with
water to a final volume of 100 ml. The mixture was ex-
tracted two times in liquid/liquid separation with 150 ml
heptane to remove the lipophilic fraction, followed by
three fold extraction in liquid/liquid separation with
150 ml ethyl-acetate to obtain polar and semi-polar frac-
tions. The ethyl acetate phase was evaporated to dryness.
After which, 50 mg of ethylacetate extract was dissolved
in 100 μl methanol and applied on SPE column (RP-18),
which was equilibrated with water and further eluted
with 3 ml of 20%, 40% and 70% acetonitrile. The fractions
that were eluted with 20%, 40% and 70% acetonitrile were
collected, combined and evaporated to dryness.
Extract preparation for in-vivo anti-inflammatory activity
Aqueous extract was prepared for in vivo testing to
mimic as close as possible the human consumption of
the stems and leaves in cooking and traditional applica-
tion. Hence, the aerial parts (comprising stem and
leaves) were dried by oven drying at a temperature of
40°C for 48 hours and shredded to 2 to 5 cm in size. A
total of 100 g dried aerial parts were then subjected to
percolation using 1000 ml of purified water and ex-
tracted at a temperature of about 80°C. The extract was
further filtered, concentrated using rotary evaporator
with the water bath temperature at 65°C and freeze-
dried. The extract was a standardised propriety extract
with quercetin-3-glucuronide (0.59%) and quercitrin
(0.27%) as marker compounds and trademarked as Line-
minus™ [29]. The dried crude extract was dissolved in
0.5% CMC (carboxymethyl cellulose) solution to pro-
duce two test doses of 100 mg/kg and 300 mg/kg re-
spectively prior to pharmacological testing.
Enzyme assays COX-1 & COX-2, 5-LOX and sPLA2
The enzyme assays are part of a preliminary screening
program for anti-inflammatory activities to justify fur-
ther in vivo test in the area of inflammation. Hence the
ability of Polygonum minus extract to inhibit COX-1 &
COX-2, 5-LOX and sPLA2 were evaluated.
Cyclooxygenase (COX-1 and COX-2) inhibition assay
The extract was dissolved in 100% DMSO to prepare a
stock concentration of 10 mg/ml. The extract was tested
in triplicates at 30 and 100 μg/ml using a commercial
COX inhibitory screening assay kit as recommended
by the manufacturer (Cayman test kit-560131, Cayman
Chemical Company). The COX inhibitor screening assaydirectly measures the amount of Prostaglandin2α produced
in the cyclooxygenase reaction. Diclofenac (MW= 296.14)
was run as the positive control for inhibition of COX-1
and COX-2. A volume of 10 μl each of test extract and ve-
hicle were diluted to 20 μl with 0.1 M Tris–HCl pH 8.0
and pre-incubated with the enzyme at 37°C for 15 minutes
prior to the addition of AA. The reaction is initiated by
addition of 10 μl 10 mM AA and the tube was incubated
at 37°C for another 2 minutes. Reaction was terminated by
addition of 50 μl 1 N HCl and saturated stannous chloride.
Assays were performed using 100 units of ovine COX-1
and human recombinant COX-2. An aliquot is removed
and the prostanoid produced is quantified spectrophoto-
metrically via enzyme immunoassay (EIA).
Lipooxygenase (5-LOX) inhibition assay
The extract was tested in triplicates at 30 and 100 μg/ml
using the LOX inhibitor screening assay kit using the
protocol recommended by the manufacturer (Cayman
test kit-766700, Cayman Chemical Company). This assay
measures the hydroperoxides generated from incubating
a 5-LOX enzyme with its substrate, AA. Nordihydro-
guaiaretic acid (MW= 302.36) was used as the positive
control. A volume of 10 μl each of test extracts and vehicle
were pre-incubated with 90 μl 5-LOX enzyme in a 96-well
plate. The reaction was initiated by addition of 10 μl 1 mM
AA and the plate was shaken for 5 minutes. Then, 100 μl
of chromogen from the test kit was added to stop enzymic
reaction and for color development. The plate was placed
on a shaker for another five minutes and absorbance at
490 nm was measured using microplate reader.
Secretory Phospholipase A2 (sPLA2) inhibition assay
The extract was tested in triplicates at 30 and 100 μg/ml
using the sPLA2 (Type V) inhibitor screening assay kit
as recommended by the manufacturer (Cayman test kit-
10004883, Cayman Chemical Company). This assay kit
contains a human recombinant Type V sPLA2 and reac-
tion mixtures. Arachidonic thioester phosphatidylcholine
was used as the positive control. A total of 10 μl each of
test extract and vehicle were pre-incubated with 25 mM
Tris–HCl buffer pH 7.5 containing 10 μl enzyme in a
96-well plate. The reaction was initiated by addition of
200 μl 1.66 mM Diheptanoylthio-PC and the plate was
shaken for 30 seconds and incubated at 25°C for 15 mi-
nutes. Further, 10 μl 5,5′-dithio-bis-(2- nitrobenzoic acid)
(DTNB) was added to stop the enzymatic reaction and to
allow for color development. The plate was placed on a
shaker for one minute to mix and absorbance was mea-
sured at 405 nm using plate reader.
Experimental animals
Thirty two male and female Wistar albino (WA) rats aged
between 8–10 weeks and weighing between 200–245 g
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conditions. The rats were placed in a room with controlled
temperature (22 ± 1°C), relative humidity (54 – 68%) and
with 12 h light/12 h dark cycles for one week before they
were used in the study. Animals were provided with
Nutrilab rodent diet (M/s Provimi Animal Nutrition Pvt.
Ltd. India) and aquaguard water ad libitum. The experi-
mental protocol was approved by the Institutional Animal
Ethics Committee (IAEC) of SPTM, India [vide approval
No. BIO/IAEC/479, dated September 03, 2012]. The study
was conducted in accordance with the recommendation
of the IAEC as well as the “Purpose of Control and
Supervision of Experiments on Animals (CPCSEA)” guide-
lines for laboratory animal facility published in the Gazette
of India, December 15th 1998.
Carrageenan-induced paw edema animal model
The test was conducted according to method based on
previous published study [30]. Briefly, 0.1 ml carra-
geenan was injected into the sub-plantar region of the
left hind-paw of each rat. The volume (ml) of induced
edema was measured using a digital plethysmometer
(IITC, USA). The rat’s foot pad became edematous soon
after the injection of carrageenan. The rats were then
randomly divided into four groups of eight (n = 8) rats
each. The rats in the four experimental groups were fed
with the various test agents 30 min after the carrageenan
injection; (i) vehicle control (CMC 0.5%); (ii) positive
control [diclofenac sodium (10 mg/kg)]; (iii) Polygonum
minus aqueous extract (100 mg/kg) and (iv) Polygonum
minus aqueous extract (300 mg/kg); respectively. The
paw volume of each rat was measured at different time
intervals (0, 2, 4, and 6 h) after carrageenan injection
using this instrument. The percentage inhibition was
calculated using the formula 100 (1-Vt/Vc), where Vc
was the mean edema volume observed in the control
group whilst Vt was the edema volume measured in
the test groups [31]. All data of each group were
expressed as mean ± SEM (n = 8). Statistical analyses
were performed with ‘Graph pad prism v4’ software
and were carried out using one way ANOVA followed
by Dunnet post-hoc test. Statistical significance was set
at p ≤ 0.05.
Results
Effect of Polygonum minus extract on in-vitro
anti-inflammatory assays
Polygonum minus ethanolic extract showed dose-
dependent inhibition of COX-1 and COX-2 with 100 and
25% inhibition respectively at 100 μg/ml (Table 1). Inhib-
ition of 5-LOX at both tested doses (30 and 100 μg/ml)
was 100%. The ethanolic extract from Polygonum minus
did not show any inhibitory activity on the sPLA2 enzyme
at both the concentrations (30 and 100 μg/ml) tested. Theethanolic extract from Polygonum minus inhibited COX-1,
COX-2 and 5-LOX enzymatic activities.
Carrageenan-induced paw edema animal model
Injection of λ-carrageenan into the sub-plantar region of
the left hind-paw rapidly induced paw edema. A signifi-
cant (p < 0.01) reduction of paw edema volume was ob-
served in the rats that were fed with the aqueous extract
from Polygonum minus (100 and 300 mg/kg b.w.) after
4 h compared to the rats that were fed with the vehicle
control (Table 2). These findings indicate that the aque-
ous extract of Polygonum minus posses potent anti-
inflammatory properties. These findings show that the
aqueous extracts (100 and 300 mg/kg b.w.) of Polyg-
onum minus inhibited the inflammatory processes in-
duced by the injection of λ-carrageenan in the paw of
rats after 4 h of oral administration.
Discussion
Dual 5-LOX/COX inhibitors are potential new drugs to
treat inflammation. These agents act by blocking the for-
mation of both PG and LT but appear to have no meas-
urable effects on the formation of lipoxin. These types of
inhibitors of inflammation with dual functions help to
avoid some of the disadvantages of selective COX-2
inhibitors [32].
Leukeotrienes (LTs) also play a major part in the in-
flammatory process [33]. These compounds are synthe-
sized via the lipooxygenase pathway with the help of the
5-LOX enzyme. The present study shows that Polyg-
onum minus extract has anti-inflammatory effects that
can inhibit both the COX-2 and 5-LOX enzymes. The
Polygonum minus has been reported to be rich with fla-
vonoids [34,35]. Flavonoids can interrupt the oxidative
generation of AA from phospholipids and reduce the
downstream production of inflammatory metabolites
from AA metabolism, oxidative damage, and induction of
inducible inflammatory pathways due to their potent
antioxidant capacity [36]. Based on a published paper
[37] it was found that a wide variety of flavonoids modu-
late the activities of AA metabolizing enzymes such as
PLA2, COX, and 5-LOX. The Polygonum minus aqueous
extract used in this study was reported to possess high
antioxidant content demonstrated by the ORAC score of
between 16,000 to 35,000 μmol TE/g [29,38]. Other stud-
ies showed that flavonoids with antioxidant capacity
could reduce the cellular conversion of AA to MDA
(malondialdehyde) in patients suffering from chronic in-
flammation [39]. Hence, it is possible that the high anti-
oxidant capacity and flavonoids content of the extract
used, have contributed to the anti-inflammatory effects
seen in in vitro testing.
In the present study the expression of reactive oxygen
species (ROS), TNF-α and nuclear factor (NF)-κBprotein
Table 1 Effect of Polygonum minus extract on COX-1 & COX-2, 5-LOX and sPLA2 inhibition
Receptor/enzyme Source Substrate % Inhibition of standard % Inhibition of Polygonum
minus at doses
Standard % of inhibition 30 μg/ml 100 μg/ml
COX-1 Ovine platelets Arachidonic acid Diclofenac (1 μM) 100 30 100
COX-2 Human recombinant Arachidonic acid Diclofenac (1 μM) 100 00 25
5-LOX Human recombinant Lipooxygenase Arachidonic acid NGDA (100 μM) 100 100 100
sPLA2 Human recombinant Type V sPLA2 Diheptanoyl thio-PC TEPC (20 μM) 90 00 00
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established antioxidant property of Polygonum minus,
the current study that evaluated its anti-inflammatory
activity and when comparing to the closely related Polyg-
onum hydropiper, also known as laksa leaf in Singapore.
Anti-inflammatory effects in vitro and in vivo for Polyg-
onum hydropiper were reported, demonstrated by the in-
hibition of mRNA expression of pro-inflammatory genes
such as COX-2, TNF-α, nuclear factor (NF)-κB and PG
[40]. A parallel to this relative of Polygonum minus was
drawn due to molecular systematic studies of the two
showing 100% similarity using molecular genetic marker
derived from four accessions of Polygonum minus [41].
These results suggest that Polygonum minus extract may
have also inhibited formation of LTs from 5-LOX and
may prevent accumulation of these key inflammatory
factors, which contribute to tissue damage through a
putative 5-LOX shunt seen with NSAIDs. The current
experiments demonstrate that, unlike NSAIDs, Polyg-
onum minus extract does not only inhibit COX me-
tabolism of AA to PGs rather it acts via inhibition of
both COX and 5-LOX enzyme activity. Other well
researched flavonoids, such as green tea catechins and
quercitin have been shown to inhibit sPLA2 thus modu-
lating the generation of AA from membrane phospho-
lipids [42,43]. The Polygonum minus extract in the tested
doses did not inhibit PLA2 activity in this study. TheTable 2 Effect of Polygonum minus extract on paw volume and
Groups & Dose
0 hr
Vehicle control (0.5% CMC) 0 mg/kg b.w. 1.35 ± 0.03
Standard (diclofenac) 1.38 ± 0.04
10 mg/kg b.w. (−2.22%)
Polygonum minus aqueous extract 1.33 ± 0.02
100 mg/kg b.w. (1.48%)
Polygonum minus aqueous extract 1.38 ± 0.03
300 mg/kg b.w. (−2.22%)
Values are expressed as mean ± SEM, n = 8 (4Male + 4Female); (−) = No inhibition.
aInhibition is reported as a percentage compared to control.
*Vehicle control vs standard (p < 0.05).
**Vehicle control vs Polygonum minus (100 mg/kg) / Polygonum minus (300 mg/kg)result suggests that Polygonum minus extract does not
have the ability to modulate the generation of AA from
membrane phospholipids produced by the destruction of
tissue. Instead, it appears that Polygonum minus extract
might possess potent active principles, which inhibits
5-LOX enzyme. With this point of view, the anti-
inflammatory activity of Polygonum minus extract was
evaluated using an established rat model to study in-
flammation. This rat model is widely used to screen the
ability of new anti-inflammatory agents to reduce local
edema induced in the rat paw by injection of an irritant
agent [44]. Carrageenan induced edema has been com-
monly used as an experimental animal model for acute
inflammation and is believed to be biphasic. The early
phase (1–2 h) of the carrageenan model is mainly me-
diated by histamine, serotonin [45]. Flavonoids includ-
ing quercetin as identified in the aqueous extract used
in this study, have been reported to possess inhibitory
effect on histamine release in mast cells which is an
anti-inflammatory reaction [46]. The second phase of
the carrageenan model is related to the release of pros-
taglandins and bradykinins [45,47]. The Polygonum minus
aqueous extract showed significant anti-inflammatory ef-
fect in λ-carrageenan-induced rat paw edema around
4 hours after administration of carrageenan. The max-
imum inhibition takes place around 4 hours during which
these anti-inflammatory mediators are expected to bepercentage inhibition in carrageenan induced paw edema
Mean paw volume ± SEM (mL) (% Inhibitiona)
2 hr 4 hr 6 hr
1.46 ± 0.03 1.50 ± 0.03 1.42 ± 0.04
1.50 ± 0.02 1.37 ± 0.03* 1.41 ± 0.04
(−2.74%) (8.66%) (0.70%)
1.47 ± 0.04 1.32 ± 0.03** 1.40 ± 0.05
(−0.68%) (12.00%) (1.41%)
1.42 ± 0.02 1.34 ± 0.02** 1.35 ± 0.04
(2.74%) (10.67%) (4.93%)
(p < 0.01).
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in vivo in another closely related plant species, Polygonum
hydropiper, which is also known as Kesum in Malay [40].
Conclusion
These studies provide evidence to show that the Polyg-
onum minus exert an anti-inflammatory effect by inhi-
biting both COX and 5-LOX activity, which was studied
using an in-vitro model and further qualified in vivo.
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